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Background
Canakinumab (CAN) is indicated for the treatment of
cryopyrin-associated periodic syndrome (CAPS) in
patients ≥2 years of age [1]. However, information on the
pharmacokinetics (PK) of CAN in patients <2 years of age
is not available. Here, we present preliminary PK data
from a phase III study in CAPS patients.
Objectives
To assess the efficacy of CAN with respect to the treatment
response in CAPS patients ≤4 years of age and to evaluate
PK and pharmacodynamics (PD) profiling of CAN.
Methods
CAN-naïve patients with confirmed CAPS aged 44 days to
4 years received open-label CAN 2 mg/kg every 8 weeks
for 56 weeks. For NOMID patients, an initial dose of
4 mg/kg was administered. Patients who did not achieve
complete response following CAN injection, or experi-
enced a flare before the next planned administration, were
eligible for dose up-titration with possible maintenance
and step wise up-titration regimens of 4, 6, or 8 mg/kg s.c.
Results
Seventeen patients, 6 patients <24 months old (44 days to
14 months; mean age = 7 months), were enrolled and
administered body weight-based (2 mg/kg up to 12 mg/kg)
doses of CAN s.c. every 8 weeks, with the exception of one
patient who received doses of 4-6 mg/kg once weekly. Of
the 6 patients <24 months old, 5 were dosed with 2 mg/kg
at each dose while 1 NOMID patient started with 4 mg/kg
and up-titrated to 8 mg/kg at last dose. Sixteen patients
achieved a complete response, with 7 patients requiring
dose escalation to achieve and/or maintain their responses.
Mean dose-normalized CAN trough concentrations at
steady-state in the patients <24 months old were similar
across the 6 patients from 44 days to 15 months, while the
range of exposures as represented by the dose normalized
trough levels overlapped with the remaining 11 study
patients >2 years old who received CAN doses ranging
from 2 mg/kg up to12 mg/kg.
Conclusions
Canakinumab is an effective treatment for patients with
CAPS aged as young as 44 days old. The preliminary PK
results demonstrated that dose-normalized canakinumab
exposure in patients <2 years old was similar to patients
>2 years supporting the utilization of weight-based dosing
in the CAPS infantile population.
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